We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First Blood-Based Diagnostic Test for Bipolar Disorder Also Differentiates Patients with Depression

By LabMedica International staff writers
Posted on 10 Jun 2022

The number of people suffering from depression is estimated at 300 million worldwide, although up to 40% of them could actually have bipolar disorder that affects more than 60 million people worldwide. More...

This chronic disorder is characterized by alternating depressive and manic phases. The depressive phases are similar to the so-called unipolar depression making the diagnosis complex and lengthy. As a result, diagnostic delays are significant, exceeding seven years on average. However, the management and treatments for bipolar disorder and depression differ significantly, making timely and reliable diagnosis paramount. Now, a new study has identified and validated a combination of blood biomarkers specific to bipolar disorder, leading to the development of the first diagnostic blood test for this disorder.

The study led by Alcediag (Montpellier, France) identified a panel of six blood biomarkers, major hallmarks of bipolar disorder. For the first time, a study, including a cohort of 410 subjects, has provided such a reliable, accurate test capable of differentiating the depressive phases of bipolar disorder from unipolar depression. The test, EDIT–B, with high diagnostic performance, specificity and sensitivity greater than 80%, was made possible thanks to the combined use of RNA editing and artificial intelligence (AI). The six biomarkers identified match modifications in the RNA sequence of genes associated with bipolar disorder.

The blood-based diagnostic test would provide biological, objective and rapidly available data to assist the physician in the process of diagnosing bipolar disorder. EDIT–B will enable them to optimize the therapeutic decision that today is plagued by the difficulty to establish a certain diagnosis. For patients, the benefits of the timely and accurate diagnosis and of the subsequent therapeutic strategy are many.

"The importance of our team's work is in harnessing the power of RNA editing, a mechanism which regulates RNA stability, splicing, gene expression and protein synthesis to create a high-performance test that is able to differentiate between unipolar depression and bipolar depression, thus paving the way to faster and more accurate diagnosis," said Dinah Weissmann, Alcediag's Deputy CEO.

Related Links:
Alcediag 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.